IDH2 and chondrosarcoma: Based on the retained CIMP-positive status and the increasing amount of hypermethylated genes in high-grade IDH mutant chondrosarcoma tumors, we expected that targeting of DNMTs by for instance decitabine and azacytidine would be effective in chondrosarcoma.